Anixa Biosciences (NASDAQ:ANIX) CEO Buys $21,760.00 in Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar acquired 8,000 shares of the stock in a transaction on Thursday, October 22nd. The shares were acquired at an average price of $2.72 per share, for a total transaction of $21,760.00. Following the acquisition, the chief executive officer owned 680,000 shares of the company’s stock, valued at approximately $1,849,600. The trade was a 1.19% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Amit Kumar also recently made the following trade(s):

• On Thursday, September 24th, Amit Kumar acquired 7,000 shares of Anixa Biosciences stock. The shares were acquired at an average price of $2.78 per share, with a total value of $19,460.00.
• On Thursday, September 10th, Amit Kumar bought 3,000 shares of Anixa Biosciences stock. The shares were acquired at an average cost of $2.75 per share, with a total value of $8,250.00.
• On Thursday, September 10th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were acquired at an average cost of $2.76 per share, with a total value of $13,800.00.
• On Friday, July 31st, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The stock was acquired at an average price of $3.47 per share, for a total transaction of $17,350.00.
• On Friday, July 24th, Amit Kumar purchased 3,000 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $3.73 per share, for a total transaction of $11,190.00.
• On Monday, July 27th, Amit Kumar purchased 3,188 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $3.37 per share, for a total transaction of $10,743.56.
• On Monday, July 27th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $3.44 per share, with a total value of $17,200.00.

Anixa Biosciences Stock Performance

ANIX traded up $0.07 during midday trading on Thursday, reaching $2.78. 153,996 shares of the company were exchanged, compared to its average volume of 208,266. The company has a market cap of $96.63 million, a price-to-earnings ratio of -8.69 and a beta of 0.47. Anixa Biosciences Inc has a one year low of $2.32 and a one year high of $5.46. The company’s fifty day moving average price is $3.01 and its 200 day moving average price is $2.98.

Anixa Biosciences (NASDAQ:ANIX) last posted its earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). As a group, sell-side analysts anticipate that Anixa Biosciences Inc will post -0.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Sanctuary Advisors LLC bought a new stake in shares of Anixa Biosciences during the 2nd quarter worth $29,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Anixa Biosciences in the 2nd quarter worth about $29,000. Integrated Wealth Concepts LLC bought a new position in Anixa Biosciences during the second quarter valued at about $30,000. Simplicity Wealth LLC bought a new position in Anixa Biosciences during the second quarter valued at about $34,000. Finally, NewEdge Wealth LLC bought a new position in Anixa Biosciences during the second quarter valued at about $35,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ANIX. Zacks Research downgraded shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Weiss Ratings upgraded shares of Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a report on Tuesday, June 30th. HC Wainwright lowered their target price on shares of Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, September 22nd. Finally, Citigroup restated a “buy” rating on shares of Anixa Biosciences in a report on Tuesday, October 6th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Anixa Biosciences presently has a consensus rating of “Hold” and an average target price of $8.00.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. Rather than marketing a broad portfolio of commercial products, the company concentrates on advancing novel therapies through research collaborations and clinical development.

Anixa’s cancer programs include a breast cancer vaccine intended to target alpha-lactalbumin, a protein associated with certain breast cancers. The program is being developed in collaboration with researchers at Cleveland Clinic.